Narrative updates are currently in beta.

Back to narrative

Update shared on15 Aug 2025

AnalystConsensusTarget's Fair Value
US$4.29
23.5% undervalued intrinsic discount
15 Aug
US$3.28
Loading
1Y
-21.2%
7D
-0.9%

HUYA's consensus analyst price target remained steady at $4.29, as a sharp drop in its future P/E ratio suggests substantially lower growth expectations, while profit margins held stable.


What's in the News


  • Completed repurchase of 22,800,000 shares (9.82% of outstanding) for $75.4 million under buyback program.
  • Recent tranche included repurchase of 1,800,000 shares (0.78%) for $5.6 million between April 1 and June 30, 2025.

Valuation Changes


Summary of Valuation Changes for HUYA

  • The Consensus Analyst Price Target remained effectively unchanged, at $4.29.
  • The Future P/E for HUYA has significantly fallen from 38.65x to 5.38x.
  • The Net Profit Margin for HUYA remained effectively unchanged, at 3.20%.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.